Oric Pharmaceuticals, Inc. ORIC Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oric Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oric Pharmaceuticals, Inc.'s additional paid-in capital?
- Oric Pharmaceuticals, Inc. (ORIC) reported additional paid-in capital of $1.14B in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Oric Pharmaceuticals, Inc.'s additional paid-in capital increased by 40.8% year-over-year, from $812.32M to $1.14B.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 18.7% compound annual growth rate (CAGR), from $456.2M to $1.08B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.